Bridgefront Capital, LLC Nuvalent, Inc. Call Options Transaction History
Bridgefront Capital, LLC
- $331 Million
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NUVL
# of Institutions
217Shares Held
60.9MCall Options Held
319KPut Options Held
211K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.28 Billion32.3% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$374 Million19.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.44MShares$315 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$215 Million0.01% of portfolio
-
Commodore Capital LP New York, NY1.86MShares$132 Million12.88% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.05B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...